Chimeric Antigen Receptor Therapy (CAR-T) is the latest breakthrough in oncology care. Simply put, it involves taking a patient’s cells, sending them to the drug manufacturer where they are re-engineered, and then infusing them back into the patient to attack the patient’s cancer. CAR-T will impact many core aspects of revenue integrity, including reimbursement.
Whether you’re new to the National Association of Healthcare Revenue Integrity (NAHRI) website or just looking to learn more about what’s available to you, our website demo can help.
Use this sample resource as a guide to outline the steps that must be taken to comply with obtaining the correct patient status order for patients who are scheduled for an inpatient-only procedure.
